Adipose tissue and metabolic syndrome: too much, too little or neither

Scott M. Grundy*,†
*Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX, USA,
†Veterans Affairs Medical Center, Dallas, TX, USA

ABSTRACT

Obesity is strongly associated with metabolic syndrome. Recent research suggests that excess adipose tissue plays an important role in development of the syndrome. On the other hand, persons with a deficiency of adipose tissue (e.g. lipodystrophy) also manifest the metabolic syndrome. In some animal models, expansion of adipose tissue pools mitigates adverse metabolic components (e.g. insulin resistance, hyperglycaemia and dyslipidemia). Hence, there are conflicting data as to whether adipose tissue worsens the metabolic syndrome or protects against it. This conflict may relate partly to locations of adipose tissue pools. For instance, lower body adipose tissue may be protective whereas upper body adipose tissue may promote the syndrome. One view holds that in either case, the accumulation of ectopic fat in muscle and liver is the driving factor underlying the syndrome. If so, there may be some link between adipose tissue fat and ectopic fat. But the mechanisms underlying this connection are not clear. A stronger association appears to exist between excessive caloric intake and ectopic fat accumulation. Adipose tissue may act as a buffer to reduce the impact of excess energy consumption by fat storage; but once a constant weight has been achieved, it is unclear whether adipose tissue influences levels of ectopic fat. Another mechanism whereby adipose tissue could worsen the metabolic syndrome is through release of adipokines. This is an intriguing mechanism, but the impact of adipokines on metabolic syndrome risk factors is uncertain. Thus, many potential connections between adipose tissue and metabolic syndrome remain to unravelled.

Keywords Adipose tissue, ectopic fat, insulin resistance, metabolic syndrome, obesity, overnutrition.

The metabolic syndrome occurs in 20–40% of the worldwide adult population [1]. This syndrome predisposes to cardiovascular disease (CVD) [2]. Its features are abdominal obesity, atherogenic dyslipidemia (elevated triglyceride [TG], elevated apolipoprotein B [apo B] and reduced high-density lipoprotein [HDL-C]), elevated blood pressure, elevated glucose levels, and pro-inflammatory and pro-thrombotic states. Those features other than abdominal obesity are commonly called metabolic risk factors. Persons with the metabolic syndrome carry an approximate twofold increase in risk for CVD [3]. Atherogenic dyslipidemia, hypertension and hyperglycaemia (diabetes) are well-established major risk factors for CVD; they are known to directly cause vascular disease. Pro-thrombotic state and pro-inflammatory states are called emerging risk factors [4,5]; they associate with CVD and are plausibly in the chain of causation, but their quantitative contributions to CVD remain uncertain.

In 1988, Reaven [6] postulated that insulin resistance underlies the metabolic syndrome. Many investigators accept this mechanism. But others see excessive nutrient energy and concomitant obesity as primary. Support for the latter view comes from the fact that most people with metabolic syndrome are overweight or obese. For example, Park et al. [7] found that among US adults the metabolic syndrome occurs in 4.6%, 22.4% and 59.6% of normal weight, overweight and obese men, respectively. Distribution was similar for US women [7]. We must therefore ask whether adipose tissue itself plays a pivotal role in causation of metabolic syndrome. This paper will examine this possibility.

Adipose tissue deficiency and metabolic syndrome

Adipose tissue is a fat storage organ. Most people believe that excess adipose tissue is detrimental. But an opposing argument is that adipose tissue defends against metabolic consequences of overnutrition. For example, patients having deficiency of adipose tissue (lipodystrophy) redistribute fat to skeletal muscle and liver [8–10]. This ectopic fat seemingly underlies severe insulin resistance, fatty liver, diabetes and hypertriglyceridemia. The metabolic syndrome phenotype accompanies...
lipodystrophy in both humans and animal models [11–13]. Conversely, some genetically obese animals manifest similar metabolic abnormalities; but when their adipose tissue is expanded more through genetic manipulation, metabolic risk factors disappear [14]. This suggests that adding more adipose tissue to existing obesity mitigates the metabolic syndrome. In animal models, adipose tissue apparently acts as a buffer against metabolic risk factors; and by the same token, buffering is impaired in the presence of adipose tissue deficiency [14]. If adipose tissue protects against the metabolic syndrome, this protection might reside in fat storage capacity. Excess fat is stored either by increasing the size or number of adipocytes. Accordingly, earlier investigators identified two types of obesity in experimental animals: hyperplastic and hypertrophic [15]. In most obese humans, both number and sizes of adipocytes are increased [16,17]. Nevertheless, Salans et al. [18] and Sjöström and Björntorp [19] reported that one or the other pattern usually dominates among obese individuals. The hypercellular form occurred in those with severe obesity of early onset. The hypertropic form, in contrast, began later in life and occurred with less severe obesity. Theoretically, hyperplastic obesity should protect against metabolic risk factors better than hypertropic obesity, because of greater potential for fat storage. Some investigators indeed favour the view that hypertrophic obesity results from deficient adipocyte replication and an insufficient lipid storage capacity [20–22].

Some insulin-resistant individuals in fact show an excess of small ‘immature’ adipocytes compared to larger cells [23,24]. Very possibly, smaller cells fail to mature into larger cells. If this failure occurs, fat storage capacity should be limited and excess fat could be redistributed to ectopic sites. Young adult men of South Asian ethnicity likewise have a high proportion of small adipocytes relative to larger adipocytes [25]; it is well known that South Asians are prone to insulin resistance, metabolic syndrome and type 2 diabetes [26–28]. In yet another report, an apparent defect in adipogenesis was noted in obese adolescents with insulin resistance [29]. All of these studies are consistent with the concept of metabolic syndrome being related to insufficient fat storage capacity.

**Obesity and metabolic syndrome: the fatty acid theory**

Beyond adipocyte size and number, adipocytes occur in different body fat pools, which may vary in metabolic characteristics. For simplicity, there are three adipose tissue locations: lower body subcutaneous, upper body subcutaneous and intraperitoneal (visceral) [30,31]. The latter two together are commonly called upper body fat. The term upper body obesity signifies accumulation of excessive adipose tissue predominately in the upper body. Excess fat in intraperitoneal adipose tissue can be called visceral obesity. In men with upper body obesity, excessive fat usually occurs in both subcutaneous and visceral pools [32]. In most women with upper body obesity, reserve fat is stored largely in subcutaneous adipose tissue; visceral adipose tissue usually is minimally expanded [32].

Upper body obesity accompanies metabolic syndrome more commonly than does lower body obesity [33–35]. There is some dispute as to which pool of upper body fat is more untoward. Some investigators postulate that excess visceral fat directly causes adverse metabolic consequences [36–41]. Others put more blame on an excess of upper body subcutaneous fat [42–46].

A widely held view is that obesity predisposes to ectopic fat and hence metabolic risk factors. The fatty acid theory identifies elevation of plasma nonesterified fatty acids (NEFA) as the mediating factor [47–54]. According to this theory, the size of adipose tissue fat stores determines plasma NEFA levels, and the latter in turn determine amounts of ectopic fat. But this premise must to be modified to some extent by body fat distribution. For example, women with upper body obesity generally have high plasma NEFA levels, whereas those with lower body obesity have near normal plasma NEFA [55]. This finding and others like it make upper body obesity the core of the fatty acid theory. Jensen [35] recently reviewed the role of three major pools of adipose tissue on NEFA metabolism. Adipose tissue compartments in lower body, upper body subcutaneous and visceral regions apparently differ in their actions on fatty acid metabolism and on their associations with metabolic risk factors. Jensen and colleagues [56–58] showed that upper body subcutaneous fat accounts for most NEFA in the systemic circulation; but when visceral adipose tissue is also expanded, portal NEFA are derived about equally from subcutaneous and visceral compartments. Higher concentrations of portal NEFA accompanying greater stores of upper body fat could explain increased liver-fat content [59,60], higher plasma levels of very low-density lipoprotein triglyceride (VLDL-TG) [31] and other components of atherogenic dyslipidemia [61,62]. At the same time, elevated systemic NEFA coming from subcutaneous adipose tissue in the upper body should contribute to insulin resistance in skeletal muscle [42,55].

In contrast to the findings with upper body obesity, persons with predominant lower body obesity are less susceptible to metabolic risk factors [31,63–69]. One idea is that lower body adipose tissue sequesters fat in ‘safe’ pools, which do not feed excess NEFA into the circulation. According to this notion, lower body adipose tissue protects against metabolic syndrome. If true, a deficiency of lower body adipose tissue could shift fat to upper body pools where NEFA release is more labile. Thus, at present it is uncertain whether ectopic fat accumulates as a consequence of too little fat storage in the
lower body or too much adipose tissue in the upper body [70]. Karpe and Finnick [63] recently summarized the association of different adipose tissue pools with metabolic syndrome. They suggest that profound functional differences exist between the upper body and lower body tissues and these differences are determined by site-specific sets of developmental genes.

It may be useful to inquire about the sources of adipose tissue TG that supply plasma NEFA. In the steady state, efflux of NEFA from adipose tissue must equal this tissue’s synthesis of TG. Adipose tissue TG comes from three sources: lipolysis of TG in lipoproteins (chylomicrons and VLDL), limited de novo lipogenesis in adipose tissue [71] and reuptake of small amounts of newly released NEFA [72]. Lipolysis of lipoprotein TG undoubtedly dominates. With this said, why is it that persons with upper body obesity have higher plasma NEFA than do those with lower body obesity? Obviously those with upper body obesity have a greater cycling of fatty acids through adipose tissue pools. The most likely reason is that people with upper body obesity consume more nutrient energy than those with lower body obesity because the former have more total body fat [31,73]. One important and unresolved question is whether visceral adipose tissue preferentially steals fatty acids from circulating lipoprotein TG and shunts them directly into the liver [74]. If so, this mechanism could enhance ectopic fat in the liver and induce its metabolic consequences [75].

Of note, release of excess NEFA from adipose tissue as the major cause metabolic syndrome seemingly does not apply to obese Pima Indians. In this intensely studied population, obese Pima men, in contrast to Caucasians, do not have elevated fasting NEFA despite having predominant upper body obesity [76]. Moreover, they have lower plasma TG and lower hepatic secretion of VLDL-TG than do comparable obese Caucasian men [76]. Obese Pima men have hepatic secretion rates for VLDL-TG and plasma TG levels similar to those of nonobese Caucasians [76,77]. In contrast, hepatic outputs of VLDL-TG and plasma TG levels are much higher in obese Caucasians compared to nonobese counterparts [75]. This apparent paradox for Pima men is unexplained. Although lower NEFA levels may protect Pima men against dyslipidemia, they do not prevent insulin resistance or type 2 diabetes. In Pima Indians, total body fat predicts insulin resistance and incidence of type 2 diabetes [78,79]; this prediction is independent of body fat distribution. A relatively low NEFA flux in obese Pima Indians casts some doubt on the fatty acid theory of insulin resistance, as noted by Lillioja and Bogardus [78]. Karpe et al. [73] likewise call for a reevaluation of the fatty acid theory of insulin resistance and metabolic syndrome.

But before dismissing the fatty acid theory altogether, however, we might ask whether other sources of fatty acids, independent of NEFA released by adipose tissue, can cause ectopic fat accumulation. When dietary fat is absorbed, chylomicron-TG enters the circulation and undergoes lipolysis by lipoprotein lipase. Most of the fatty acids released by lipoprotein lipase are taken up immediately by adipose tissue and incorporated into TG. But normally during lipolysis, about one-quarter to one-third of newly hydrolysed fatty acids are not taken up into adipose tissue and spill over into the circulation as NEFA. The latter theoretically could enhance ectopic-lipid accumulation [74,80–82]. The percentage spillover is reduced by obesity [83], especially by lower body obesity [82]. Excess adipose tissue seemingly mitigates spillover of fatty acids through increased adipose tissue uptake. But even so, sequestration of more postprandial fatty acids in adipose tissue as TG must be only temporary. To avoid progressive accumulation of fat in adipose tissue, fatty acids must be returned to the circulation during fasting.

Dietary carbohydrate is another source of plasma NEFA, but through an indirect route. A high intake of carbohydrates will induce hepatic lipogenesis, raise hepatic TG content [80,84] and increase plasma VLDL-TG levels [85,86]. Lipolysis of plasma VLDL-TG derived from de novo lipogenesis thus will contribute to adipose tissue TG. The latter in turn will feed more NEFA to muscle, where it can raise insulin resistance. Thus, for fatty acid metabolism, it makes little difference whether nutrient energy is consumed as fat or carbohydrate. Carbohydrates become fat through de novo lipogenesis. Ratios fat-to-carbohydrate in the diet have little effect on amounts of fat stored in adipose tissue; and neither does the degree of insulin resistance in obese persons depend on relative proportions of dietary fat and carbohydrate [87]. Whether high-carbohydrate diets affect insulin sensitivity in ways other than through increased lipogenesis is uncertain.

In spite of several cavets, the fatty acid theory of metabolic syndrome still lives. There are a variety of pathways whereby muscle and liver may be overloaded with lipid so as to engender metabolic risk factors, particularly insulin resistance and dyslipidemia. Adipose tissue is only one of these pathways through which fatty acids can flux. At present, we cannot assume that there is a one-to-one relationship between adipose tissue stores and ectopic fat. But high levels of ectopic fat could still be a final common pathway to the metabolic syndrome.

**Emerging risk factors of adipocyte origin**

In recent years, another theory has been advanced to explain why obesity might foster the metabolic syndrome. Adipose tissue is known to release a variety of products including leptin, adiponectin, inflammatory cytokines, resistin, visfatin, plasminogen activator inhibitor-1 (PAI-1) and angiotensinogen. These products, often called adipokines, can be looked upon as emerging metabolic risk factors. Some of these can be considered negative risk factors in that they potentially protect against
diabetes and CVD; others are positive risk factors because they may predispose to metabolic disease or CVD. In fact, a very large number of potentially bioactive molecules have been found to be released by adipose tissue [88]. There has been extensive research and discussion of how various adipokines may modify systemic metabolism [89]. To the extent to which adipokine release is modified in obese persons, the potential exists for a direct link between adipose tissue and metabolic risk factors.

Leptin, one factor released by adipose tissue, is known to dampen energy intake [90]. In this regards, it can be considered a protective factor. Humans who are genetically deficient in leptin have voracious appetites and develop severe obesity [91,92]. In otherwise normal individuals, when adipose tissue expands, leptin release is enhanced [93]. Obese persons have high leptin levels, which theoretically could curtail further food intake through suppression of the appetite [94]. Conversely, generalized lipodystrophy is accompanied by leptin deficiency, which leads to excessive food intake. Humans with generalized lipodystrophy usually exhibit severe hypertriglyceridemia and glucose intolerance. These abnormalities might be attributed to a lack of fat storage capacity in adipose tissue; but in fact, they appear to be due largely to excessive food intake. In lipodystrophic patients, leptin replacement diminishes appetite and curtails metabolic risk factors [95]. One large epidemiologic study suggested that caloric consumption in obese individuals is inversely related to leptin levels [96]. But this finding is not definitive. Whether the rise in leptin with obesity acts as a governor on food intake is uncertain. On the other hand, many reports suggest that leptin suppresses the metabolic syndrome independent of its effects on appetite [90,97]. Perhaps in this way leptin acts as a protective factor.

Another leading candidate for a protective adipokine is adiponectin. Many studies show that adiponectin levels are inversely associated with metabolic risk factors [98]. Adiponectin release is reduced in obese persons, which opens the door to adverse consequences. But to definitively prove a systemic role for adiponectin, studies are needed in individuals with genetic deficiencies of this protein. So far however, few families with genetically reduced adiponectin have been identified. An exception is one family where a gene mutation impairs assembly of high-molecular-weight adiponectin; here, an adiponectin deficiency associated with early onset obesity and metabolic syndrome [99]. Other studies have examined effects of polymorphisms in the adiponectin gene in the general population. In these studies, no consistent relation has been found between variation in the adiponectin gene and insulin resistance [100,101]. The strength of the action of adiponectin to suppress metabolic risk factors thus remains uncertain.

One emerging metabolic risk factor is a pro-inflammatory state [102]. Excess adipose tissue may contribute to this putative risk factor. For example, obesity is accompanied by macrophage accumulation in adipose tissue [103]. Presumably death of lipid-engorged adipocytes stimulates an influx of macrophages. Cytokines released in this process apparently spill into the circulation and possibly cause systemic inflammation and/or insulin resistance [104]. The best evidence for a systemic response to localized inflammation in adipose tissue is an increase in plasma C-reactive protein (CRP) [105–107]. The association of a high CRP with both diabetes and CVD is consistent with a role of inflammation induced by adipose tissue in systemic metabolic disease [108–110]. Of course, this association does not necessarily signify causation. A more direct test of the pro-inflammatory hypothesis is an ongoing clinical trial to determine whether a low-dose of methotrexate, an anti-inflammatory drug, will reduce risk for CVD and diabetes [111].

Another emerging metabolic risk factor is a pro-thrombotic state [102]. Although a variety of pro-thrombotic factors have been noted in patients with metabolic syndrome, the most consistent finding is an increase in plasma PAI-I. Upper body adipose tissue appears to be a source of circulating PAI-I [112,113]. Prospective studies indicate that higher levels of PAI-I frequently accompany acute cardiovascular syndromes [114,115]. The action of PAI-I to block plasminogen activation could initiate or worsen thrombotic events, although direct causation is difficult to prove.

Hypertension is major risk factor accompanying the metabolic syndrome. A large body of evidence implicates obesity in the causation of hypertension [116,117]. Several mechanisms have been proposed: enhanced renal reabsorption of sodium, expansion of intravascular volume, activations of the renin–angiotensin–aldosterone system and sympathetic nervous system, release of angiotensinogen from adipose tissue, and insulin resistance [118–120]. Whether hypertension is mediated through adipokines remains to be confirmed, but several have been implicated, that is, increased leptin [121], reduced adiponectin [122], inflammatory cytokines [123] and angiotensinogen.

In spite of a growing body of literature implicating adipokines in the pathogenesis of the diabetes and CVD, a solid connection is by no means definitive. Most of the evidence falls under the category of association, hence the term emerging risk factor. The adipokine theory of metabolic syndrome derives largely from animal studies and epidemiology. The findings are provocative; but genetic studies in families with adipokine deficiency or therapeutic trials with adipokine blockers or enhancers will be required to nail down causative connections.

Overnutrition vs. adiposity

The severe metabolic syndrome observed in persons with lipodystrophy provides insight into causation of the syndrome.
In lipodystrophic individuals, leptin deficiency induces overnutrition. Their excessive caloric intake obviously overwhelms metabolic defences and leads to severe ectopic fat accumulation and its consequences. These are largely reversed by leptin therapy. The extent to which a lack of fat storage capacity with lipodystrophy independently produces metabolic risk factors is uncertain.

What are the defences against overnutrition? Storage of excess energy in adipose tissue during weight gain is the first defence. When weight stabilizes, adipose no longer serves this role. Storage capacity appears to be variable. For example, fat storage capacity in persons with predominant hyperplastic obesity appears to be greater than in those with hypertrophic obesity. Once weight is stabilized, however, obese people still consume more energy than do nonobese individuals [124,125]. It is doubtful that white adipose tissue alone can oxidize all the excess energy consumed by obese persons. As a matter of fact, weight gain is accompanied by an increase in lean body mass [126]. As obesity develops, there is an almost 1 : 1 increase in fat and lean mass [78]. A significant portion of the increase in weight occurs in the form of skeletal muscle [127,128]. Consequently, disposal of excess energy by more lean body mass could help to buffer the caloric overload in obese individuals. But when excess calories are not completely buffered by increases in adipose tissue and muscle, ectopic fat will accumulate in skeletal muscle, liver and perhaps other tissues. As discussed before, this ectopic fat may well be a driver of the metabolic syndrome [129]. In the final analysis, the metabolic syndrome is the consequence of dietary nutrient overload that cannot be adequately buffered by various metabolic defences.

The best evidence for the critical role of nutrient intake as the primary factor responsible for the metabolic syndrome comes from studies in patients undergoing bariatric surgery [130,131]. In these studies, caloric intake is reduced by surgery, but in most patients, significant obesity remains. Meta-analysis of these studies shows dramatic reductions and often total reversal of metabolic abnormalities even in the presence of substantial residual obesity [130]. Another trial, the Diabetes Prevention Program [132], illustrates the potential of energy restriction to modify metabolic risk. In this large study of individuals with prediabetes, caloric restriction reduced total body weight by only 5–10%, but conversion to diabetes was dramatically decreased; at the same time, the incidence of new-onset metabolic syndrome was curtailed and metabolic risk factors were strikingly reduced [133,134]. These benefits occurred in the face of substantial remaining obesity. Studies on the pathways whereby nutrient overload enhances metabolic risk are of great interest. The role of adipose tissue both in protection and causation is particularly germane. But at this time, it is unclear whether amounts or characteristics of adipose tissue present at constant body weight play a major role buffering excess energy or whether an excess of adipose tissue independent of caloric intake is a direct cause of metabolic syndrome.

Nonobese metabolic syndrome

Some people exhibit the metabolic syndrome even in the absence of obesity [135]. Examples include lean adults with primary insulin resistance of muscle [136,137], offspring of parents with diabetes [138], lean South Asians [28,139] and some genetic forms of hypertriglyceridaemia [140]. These examples appear to represent genetic susceptibility to metabolic syndrome. On the other hand, many people are resistant to this syndrome even in the presence of obesity [141]. They presumably are genetically resistant. The mechanisms responsible for differences in expression of the metabolic syndrome at each end of the genetic spectrum are ripe for research.

Therapeutic implications

These considerations suggest that for prevention or treatment of metabolic syndrome priority should be given to energy balance – either decreasing nutrient energy or enhancing its expenditure. For the population as a whole, this will require behavioural modification of lifestyle habits. But for individuals who fail to reverse the metabolic syndrome through behaviour modification, pharmacological approaches to suppressing the appetite would be welcome. For some, bariatric surgery may be the best option; the improvement of the syndrome following surgery has been impressive [130]. If caloric restriction fails to reverse the syndrome, it will be necessary to treat each risk factor individually. To reduce all metabolic risk factors, multiple drugs may be required. The disadvantages to polypharmacy for management of multiple metabolic risk factors however are well known [142].

Address

Center for Human Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Suite Y3.206, Dallas, TX 7539-9052, USA (S. M. Grundy); Veterans Affairs Medical Center, 4600 South Lancaster Road, Dallas, TX 75216, USA (S. M. Grundy).

Correspondence to: Scott M. Grundy, Center for Human Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Suite Y3.206, Dallas, TX 7539-9052, USA. Tel.: 214 648 2890; fax: 214 648 4837; e-mail: scott.grundy@utsouthwestern.edu

Received 1 June 2015; accepted 15 August 2015
References

1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629–36.
2. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92:399–404.
3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ,weet al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.
4. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006;367:651–8.
5. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205–13.
6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.
7. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003;163:427–36.
8. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220–34.
9. Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004;33:305–31.
10. Decaudain A, Vantyghem MC, Guerci B, Hécart AC, Auclair M, Reznik Y et al. New metabolic phenotypes in lipodystrophies: LMNA mutations in patients with severe metabolic syndrome. J Clin Metabolol 2007;92:4835–44.
11. Huang-Doran I, Siegle A, Rochford JJ, O’Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol 2010;207:245–55.
12. Savage DB. Mouse models of inherited lipodystrophy. Dis Model Mech 2009;2:554–62.
13. Vermochet C, Damilano F, Mourier A, Bezy O, Mori MA, Smyth G et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. FASEB J 2014;28:4408–19.
14. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621–37.
15. Johnson PR, Hirsch J. Cellularity of adipose depots in six strains of genetically obese mice. J Lipid Res 1972;13:2–11.
16. Björntorp P, Bengtsson C, Blohmé G, Jonsson A, Sjöström L, Tibblin E et al. Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism 1971;20:927–35.
17. Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M, Huot C et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283–91.
18. Salans LB, Cushman SW, Weismann RE. Studies of human adipose tissue. Adipose cell size and number in nonobese and obese patients. J Clin Invest 1973;52:929–41.
49 Boden G, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. *Hepatology* 2007;46:716–22.

50 Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? *Hepatology* 2009;49:791–801.

51 Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship with Cardiometabolic Risk/Intra-Abdominal Adiposity. *Am J Clin Nutr* 2012;96:714–26.

52 Ryo M, Kishida K, Nakamura T, Yoshizumi T, Funahashi T, Shimomura I. Clinical significance of visceral adiposity assessed by computed tomography: a Japanese perspective. *World J Radiol* 2014;6:409–16.

53 Shadid S, Koutsari C, Jensen MD. Direct free fatty acid uptake into adipose tissue during high fat feeding in healthy lean men and women. *Am J Physiol Endocrinol Metab* 2013;304:E177–87.

54 Altri CF, Cotton RT, Pinnick KE, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance. *J Lipid Res* 2015;56:2441–9.

55 Nelson RH, Basu R, Johnson CM, Rizza RA, Miles JM. Splanchnic spillover of extracellular lipase-generated fatty acids in overweight and obese humans. *Diabetes* 2007;56:2878–84.

56 Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. *Nature* 2014;510:84–91.
lips: lack of influence of body weight or plasma insulin. J Lipid Res 1980;21:1032–41.
77 Grundy SM, Mok HY, Zech L, Steinberg D, Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest 1979;63:1274–83.
78 Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988;4:517–40.
79 Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care 2003;26:2556–61.
80 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1543–51.
81 Barrows BR, Timlin MT, Parks EJ. Spillover of dietary fatty acids and use of serum nonesterified fatty acids for the synthesis of VLDL-triaclyglycerol under two different feeding regimens. Diabetes 2005;54:2668–73.
82 Almazdo JP, Singh E, Howell LA, Grothe K, Vlazny DT, Smailovic A et al. Spillover of fatty acids during dietary fat storage in type 2 diabetes: relationship to body fat depots and effects of weight loss. Diabetes 2013;62:1897–903.
83 McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes 2011;60:47–55.
84 Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoeenergetic diets. Ann J Clin Nutr 2003;77:43–50.
85 Ahrens EH Jr, Hirsch J, Oette K, Farquhar JW, Stein Y. Carbohydrate-induced and fat-induced lipemia. Trans Assoc Am Physicians 1961;74:134–46.
86 Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. N Engl J Med 1986;314:745–8.
87 Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes 1992;41:1278–85.
88 Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 2012;6:91–101.
89 Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939–49.
90 Friedman JM, Mantzoros CS. 20 years of leptin: from the discovery of the leptin gene to leptin in our therapeutic armamentarium. Metabolism 2015;64:1–4.
91 Montaqué CT, Farooqi S, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903–8.
92 Clement K, Vaisse C, LahLOUR N, Cabrol S, PELLoux V, Cassudo D et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398–401.
93 Maffei M, Halas J, Ravussin E, Prattley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155–61.
94 Flier JS. Clinical review 94: what’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 1998;83:1407–13.
95 Oral EA, Simha V, Ruiz E, Andewell A, Premkumar A, Snell P et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570–8.
96 Nakamura Y, Ueshima H, Okuda N, Murakami Y, Miura K, Kita Y et al. Serum leptin and total dietary energy intake: the INTERLIPID Study. Eur J Nutr 2013;52:1641–8.
97 DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol 2014;223:T71–81.
98 Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Cur Diab Rep 2003;3:207–13.
99 Bueno AC, Sun K, Martins CS, Elias J Jr, Miranda W, Tao C et al. A novel ADIPOQ mutation (p. M40K) impairs assembly of high-molecular-weight adiponectin and is associated with early-onset obesity and metabolic syndrome. J Clin Endocrinol Metab 2014;99:E683–93.
100 Sandy An S, Palmer ND, Hanley AJ, Ziegler JT, Mark Brown W, Freedman BI et al. Genetic analysis of adiponectin variation and its association with type 2 diabetes in African Americans. Obesity (Silver Spring) 2013;21:E721–9.
101 Cao D, OuYang S, Liu Z, Ma F, Wu J. Association of the ADIPOQ T45C polymorphism with insulin resistance and blood glucose: a meta-analysis. Endocr J 2014;61:437–46.
102 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.
103 Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:8796–808.
104 Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635–45.
105 Chang C, Garcia-Garcia AB, Hamilton E, Shah B, Meguro S, Grundy SM et al. Metabolic syndrome phenotype in very obese women. Metab Syndr Relat Disord 2007;5:3–12.
106 Khera A, Vega GL, Das SR, Ayers C, McGuire D, Grundy SM et al. Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab 2009;94:3251–8.
107 Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2013;21:E439–47.
108 Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.
109 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–34.
110 Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818–25. Review.
111 Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199–207.
112 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860–7.
113 Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. *Diabetologia* 2001;44:2025–31.

114 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. *Circulation* 1996;94:575–63.

115 Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. *Circulation* 1998;98:2241–7.

116 Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressures in Korean men and women: the Korean National Blood Pressure Survey. *J Hypertens* 1994;12:1433–7.

117 Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and predictors of hypertension in young adults: the Framingham Offspring Study. *Preo Med* 1987;16:234–51.

118 Reaven GM. Relationship between insulin resistance and hypertension. *Diabetes Care* 1991;14:33–8.

119 Hall JE. Pathophysiology of obesity hypertension. *Curr Hypertens Rep* 2000;2:139–47.

120 Hall JE, da Silva AA, do Carmo JM, Dubinjon J, Hamza S, Munusamy S et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. *J Biol Chem* 2010;285:17271–6.

121 Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM et al. Leptin mediates the increase in blood pressure associated with obesity. *Cell* 2014;159:1404–16.

122 Rojas E, Rodríguez-Molina D, Bolli P, Israelí ZH, Faria J, Fudilio E et al. The role of adiponectin in endothelial dysfunction and hypertension. *Curr Hypertens Rep* 2014;16:463.

123 Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. *JAMA* 2003;290:2945–51.

124 Welle S, Forbes GB, Statt M, Barnard RR, Amatruda JM. Energy expenditure under free-living conditions in normal-weight and overweight women. *Am J Clin Nutr* 1992;55:14–21.

125 Swinburn BA, Sacks G, Lo SK, Westerterp KR, Rush EC, Rosenbaum M et al. Estimating the changes in energy flux that characterize the rise in obesity prevalence. *Am J Clin Nutr* 2009;89:1723–8.

126 Forbes GB. The companionship of lean and fat. In: Ellis KJ, Eastman JD, editors. *Human Body Composition*. New York, NY: Plenum Press; 1993: pp 3–14.

127 Albu JB, Kovera AJ, Allen L, Wainwright M, Berk E, Raja-Khan N et al. Independent association of insulin resistance with larger amounts of intermuscular adipose tissue and a greater acute insulin response to glucose in African American than in white non-diabetic women. *Am J Clin Nutr* 2009;82:1210–7.

128 Leon B, Jenkins S, Pepin K, Chaudhry H, Smith K, Zales G et al. Insulin and extremity muscle mass in overweight and obese women. *Int J Obes (Lond)* 2013;37:1560–4.

129 Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. *N Engl J Med* 2014;371:1131–41.

130 Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA* 2004;292:1724–37. Review. Erratum in: *JAMA*. 2005;292:1728.

131 Clifton PM. Bariatric surgery: results in obesity and effects on metabolic parameters. *Curr Opin Lipidol* 2011;22:1–5.

132 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.

133 Orchard TJ, Temproma S, Goldberg R, Haffner S, Ratner R, Marcovina S et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. *Ann Intern Med* 2005;142:611–9.

134 Goldberg RB, Mathet K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. *Arterioscler Thromb Vasc Biol* 2012;32:2077–90.

135 Ruderman NB, Schneider SH, Bercztold P. The, “metabolically-obese”, normal-weight individual. *Am J Clin Nutr* 1981;34:1617–21.

136 Petersen KE, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc Natl Acad Sci U S A* 2007;104:12587–94.

137 Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. *JAMA* 2007;293:51.

138 Altinli S, Elevli M, Ozkul AA, Kara PG, Karsidag K, Dogru M. Insulin resistance and metabolic syndrome in children of parents with diabetes mellitus. *J Pediatr Endocrinol Metab* 2007;20:431–6.

139 Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. *Metab Syndr Relat Disord* 2009;7:497–514.

140 Skoumas J, Papadimitriou L, Pitsavos C, Masoura C, Giotas N, Chrysohoou C et al. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia. *Metabolism* 2007;56:135–41.

141 Grundy SM, Neeland B, Turer AT, Vega GL. Ethnic and gender susceptibility to metabolic risk. *Metab Syndr Relat Disord* 2014;12:110–6.

142 Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. *Nat Rev Drug Discov* 2006;5:295–309.